Early almotriptan intervention ameliorates migraine symptoms

Early acute migraine intervention with almotriptan [Axert, Almogran] within 1 hour of symptom onset provides significant clinical outcomes in patients with migraine, according to results of the AEGIS* trial, presented at the 58th Annual Meeting of the American Academy of Neurology (AAN) [San Diego, California, US; April 2006]. Compared with placebo recipients, the 2-hour pain-free rate was significantly higher in patients treated with almotriptan. Furthermore, significant between-group differences in favour of almotriptan were demonstrated with respect to sustained pain-free rate, pain relief, functional disability, headache intensity, migraine-associated symptoms and use of rescue medication. An analysis of the AEGIS and AIMS** early intervention studies of almotriptan showed that patients who had mild or moderate headache had significantly better clinical outcomes compared with those patients with severe headache.